ESMO TAT, known as “The Home of Phase I in Oncology” offers participants a glimpse of the future of targeted anticancer therapies, focusing on promising new anticancer targets and agents, with a particular focus on those in early phase clinical development.
This is the place where stakeholders from academia and industry get the chance to discuss with clinicians, researchers, and regulators the global dissemination of knowledge and clinical research expertise in the field of innovative cancer therapeutics, to the benefit of cancer patients worldwide.
The 2022 edition of the congress unveiled the most exciting topics coming into the clinic at the moment, with scientific sessions bridging from new cellular therapies to target agents, from ADCs to protein degraders of molecular glues, and more.